Sun Pharma eyes mid-high single digit revenue growth in FY26, bets on innovation

December 26, 2025
Uncategorized

Sun Pharmaceutical Industries targets mid- to high-single digit topline growth in FY26, focusing on innovative medicines and increased R&D investment.

Sun Pharma eyes mid-high single digit revenue growth in FY26, bets on innovation

Leave a ReplyCancel Reply

Sensex Today | Stock Market LIVE Updates: Nifty futures hint at a negative start; 25,000 in focus

Fractal Analytics IPO listing today: AI play may see modest start

Olympus shares slump to 8-month low, down 11% after Japanese giant cuts income forecast

Asia shares becalmed by holidays, dire Japan data

Manappuram Finance shares in focus after RBI clears Bain Capital stake buy